FIGURES




FIG. 1



FIG. 2



FIG. 3



FIG. 4



FIG. 5




FIG. 6


Final formulation
G2B-SN38-CPT-20-5-5
CPT and SN-38 (both 1 mg/mL) in vehicle
G2B-SN38-CPT-20-2-2
CPT and SN-38 (both 0.5 mg/mL) in vehicle
Photo
Turbidity
-
+
-
+

FIG. 7


Cell line: HSJD-DIPG-007 (DIPG)
% of control
100
80
60
40
20
0
10-6
10-4
10-2
100
102
Concentration (μM)
Irinotecan
G2B-002-20-9
SN-38

FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




I

FIG.13




FIG.14


G2B-002-20-16 10 mg/kg
G2B-002-20-16 1 mg/kg
G2B-002-20-9 10 mg/kg
G2B-002-20-9 1 mg/kg
G2B-002-10-5 1 mg/kg
Irinotecan 10 mg/kg
Control (saline solution)

FIG. 15


SN-38 lactone (ng/g retina)
10000
1000
100
10
1
0 1 2 3 4 5 6 7 8
Time (h)
G2B-002, 10 mg/kg
G2B-002, 1 mg/kg
Irinotecan, 10 mg/kg

FIG. 16


2×10-5
1.5×10-5
1×10-5
5×10-6
0
Papp/cm*s-1
G2B-002-20-9
G2B-002-10-5
G2B-002-20-16
SN38

FIG. 17